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Abstract: Diabetic nephropathy (DN) is a major complication of diabetes and is caused  
by an imbalance in the expression of certain genes that activate or inhibit vital cellular 
functions of kidney. Despite several recent advances, the pathogenesis of DN remains far 
from clear, suggesting the need to carry out studies identifying molecular aspects, such as 
gene expression, that could play a key role in the development of DN. There are several 
techniques to analyze transcriptome in living organisms. In this study, the suppression 
subtractive hybridization (SSH) method was used to generate up- and down-regulated 
subtracted cDNA libraries in the kidney of streptozotocin (STZ)-induced diabetic rats. 
Northern-blot analysis was used to confirm differential expression ratios from the obtained 
SSH clones to identify genes related to DN. 400 unique SSH clones were randomly chosen 
from the two subtraction libraries (200 of each) and verified as differentially expressed. 
According to blast screening and functional annotation, 20.2% and 20.9% of genes were 
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related to metabolism proteins, 9% and 3.6% to transporters and channels, 16% and 6.3% 
to transcription factors, 19% and 17.2% to hypothetical proteins, and finally 24.1 and 17.2% 
to unknown genes, from the down- and up-regulated libraries, respectively. The down- and 
up-regulated cDNA libraries differentially expressed in the kidney of STZ diabetic rats 
have been successfully constructed and some identified genes could be highly important  
in DN.  
Keywords: diabetes mellitus; diabetic nephropathy; cDNA libraries; suppression 
subtractive hybridization 
 
1. Introduction  
Diabetic nephropathy (DN) is one of the most frequent microvascular complications of diabetes 
mellitus, and develops in 15–40% of patients with Type 1 and Type 2 diabetes. The course of renal 
disease might be similar for both types of diabetes. This complication is associated with a considerable 
increase in morbidity and mortality, being the leading cause of end-stage renal failure (ESRD) [1,2]. 
The highest incidence of ESRD has been reported for Taiwan, United States, Mexico, China and Japan, 
and has been found to be related to a higher prevalence of diabetes mellitus. For example, in Jalisco, 
Mexico, 60% of newly diagnosed ESRD patients had a primary diagnosis of diabetes [3]. 
Diabetes is characterized by hyperglycemia, an abnormal elevation in the blood glucose level, and it 
has been associated with oxidative stress [4] and inflammatory processes [5,6], which cause DN. This 
complication is related to specific morphological and functional renal alterations. They include 
hyperplasia/hypertrophy of various cell types of the glomeruli and tubules [7], producing changes of 
renal function, characterized by an increase in urinary albumin excretion in early stages and by 
proteinuria in advanced stage, which is also considered as a decline in renal function [8]. 
In recent years, it has been reported that several hemodynamic and metabolic factors are involved in 
the pathogenesis of DN [9], such as advanced glycation end-products and the aldose reductase/polyol 
pathway, vasoactive factors such as angiotensin II and endothelin. Also vasodilator factors, such as nitric 
oxide, are related to DN. In addition, protein kinase C, an intracellular signaling molecule, can be 
activated by many of these metabolic and hemodynamic factors to stimulate prostaglandin and 
cytokine production. Several growth factors, such as the transforming growth factor beta, vascular 
endothelial growth factor and platelet-derived growth factor, are involved in the pathogenesis of 
diabetic kidney disease [10]. 
Despite several recent advances, the pathogenesis of DN remains far from clear [11]. Therefore, 
there is current interest in identifying signaling molecules that play a key role in the management of 
DN. This could be achieved with the use of newly developed tools like microarray technology, 
proteomics and transcriptomics. 
Several pathologies, such as DN, show a differential gene expression pattern, which could be 
identified by these techniques. Therefore, subtractive suppression hybridization (SSH) can be used to 
clone the differentially regulated genes. During SSH-polymerase chain reaction (PCR), the population 
of mRNAs in one condition is subtracted from the mRNAs from another contrasted condition,   Int. J. Mol. Sci. 2011, 12 8433 
 
thus isolating differentially expressed genes, which can be further characterized [12]. By using   
the SSH technique, a number of genes from STZ-induced diabetic mouse kidneys were identified, such 
as Tim44 (translocase of inner mitochondrial membrane-44), RSOR/MIOX (renal specific   
oxido-reductase/myo-inositol oxygenase), UbA52 and Ras-like GTPase, Rap1b [3], among others. 
However, the isolation and identification of new biomarkers could serve as therapeutic targets for the 
amelioration of DN. 
One of the most common models used for the evaluation of these alterations is the spontaneously 
and chemically-[e.g., streptozotocin (STZ)] induced rat model of type 1 diabetes, in addition to rat 
models of type 2 diabetes. These animals display early renal alterations that share similarities to the 
early changes seen in human diabetes [10]. Diabetes, induced in Wistar rats by a single intraperitoneal 
injection of STZ (50 mg/kg), causes: severe destruction of the kidney and glomerular and 
tubulointerstitial lesions, such as glomerular sclerosis, atrophy, interstitial expansion; and interstitial 
cellular infiltration, after four weeks [13]. Therefore, in order to detect differential gene expression 
involved in DN, we used the well-known model of STZ induced diabetes in rats to apply the SSH 
technique in order to compare between normal and diabetic kidneys. 
Therefore, the aim of the present work was to determine a differential transcriptomic profile during 
DN in diabetic rats by using SSH. Some identified genes are discussed in order to interpret their 
possible role in DN. 
2. Results and Discussion  
2.1. Biochemical Parameters in Healthy and Diabetic Rats 
Induced experimental diabetes in animals was performed using a single injection of 50 mg/kg B.W. 
of STZ. This dose causes partial destruction of pancreatic β-cells responsible for producing and 
secreting insulin into the body, therefore, rats showed type 1 diabetes. The lack of insulin causes a 
decrease in the incorporation of glucose into peripheral tissues such as adipose and muscle, thereby 
increasing blood glucose [14]. In this experiment, STZ-injected rats showed a significant increase in 
blood glucose with a decrease in insulin levels, producing a diabetic condition (Table 1). 
Regarding physiological parameters after induction of diabetes, significant differences in 
consumption of food and water, growth retardation and urine volume were observed in diabetic 
animals in comparison to healthy animals. Also, a decreased creatinine clearance (Ccr) was observed 
in diabetic animals compared with nondiabetic rats (P < 0.05). On the other hand, markers of renal 
damage in urine such as urea, albumin and protein excretion showed an increase in diabetic rats 
compared with those values obtained in nondiabetic animals (Table 1). Additionally, blood urea 
nitrogen and serum creatinine levels in diabetic rats indicate progressive renal damage, which is 
considered to be an indication of altered glomerular filtration rate in DN [15]. Our results are similar to 
those reported by Akbarzadeh et al. [16]. Likewise in this experiment, diabetic rats showed an increase 
in kidney weight compared to healthy rats (P < 0.05). In addition, these results are consistent to those 
described by Yamabe et al. [17], who observed an increase in kidney weight in STZ-induced diabetic 
male Wistar rats compared to healthy rats. This could be related to kidney hyperplasia caused   Int. J. Mol. Sci. 2011, 12 8434 
 
by inflammation. Overall, these results suggest the presence of abnormalities in the renal function of  
diabetic animals. 
Table 1. Biochemical parameters of healthy and streptozotocin (STZ)-diabetic rats. 
Parameters  Healthy control  Diabetic control 
Physiological:    
Body weight (g)  379.7 ± 12.2 
a  248.6 ± 8.3 
b 
Kidney weight (g/100 g BW)  0.60 ± 0.01 
b  0.90 ± 0.02 
a 
Food intake (g/rat/day)  28.5 ± 0.6 
b 56.7 ± 1.9 
a 
Water intake (mL/rat/day)  40.6 ± 3.6 
b 385.8 ± 9.6 
a 
Urine output (mL/rat/day)  22.4 ± 2.9 
b 43.6 ± 3.2 
a 
Creatinine clearance 
(mL/min) 
1.63 ± 0.04 
a  0.78 ± 0.03 
b 
Urine (mg/24h):     
Albumin  1.3 ± 0.2 
b  2.6 ± 0.4 
a 
Protein   4.3 ± 0.3 
b  7.2 ± 1.2 
a 
Urea  5.1 ± 0.6 
b 30.4 ± 3.2 
a 
Serum:      
Fasting glucose (mg/dL)  52.0 ± 2.0 
b  356 ± 29.1 
a 
Insulin (µU/mL)  19.1 ± 3.4 
a  9.9 ± 1.0 
b 
Urea (mg/dL)  23.7 ± 1.8 
b 80.1 ± 4.9 
a 
Values are presented as means ± SEM (n = 8). a, b Mean values within a row with unlike superscript letter 
were significantly different (P < 0.05; by the t-student test). 
2.2. Kidney Histopathology  
Besides the biochemical changes in diabetic rats, morphological changes in kidney were carried out 
to confirm the development of DN. One of the morphological changes associated to DN is mesangial 
expansion due to increased mesangial matrix deposition, a mild increase in mesangial cellularity, and 
hypertrophy of mesangial cells [18]. Sections of rat kidney cortices obtained from the two 
experimental groups were stained with Hematoxylin-Eosin (H-E) and the results are shown in Figure 1. 
Figure 1. Histological analysis of renal changes in (a)  healthy and (b) diabetic rats. 
Representative photomicrographs of H-E stained renal cortex. 
 I
H
(
s
(
in
r
p
lo
g
th
2
o
E
m
I
a
o
2
o
a
Int. J. Mol. S
The kidn
However, ki
Figure 1b). 
structural ab
glomeruli, t
In recent
n different 
rodent mod
progression 
ow number
genes involv
herapeutic s
2.3. Differen
By using 
of diabetic r
EST’s obtai
membranes 
t was obser
a marked dif
of cDNA arr
Figure
Panel 
2.4. Analysis
EST’s, ba
of these clon
and the resu
Sci. 2011, 1
neys of hea
idneys of th
These resul
bnormalities
tubulointers
t years, ge
animal mo
els of diab
of this dise
r of those g
ved in this d
strategies. 
ntial Expres
SSH techn
rats. Northe
ined from 
(100 to eac
rved that 88
fferential ex
rangements
e 2. Typica
left: probe f
s of Sequen
ased on the
nes were co
ults from th
12 
althy rats sh
he diabetic 
lts are simil
s of DN are
stitium, and 
ne expressi
odels, such 
betes. These
ease, but the
genes are co
disease that
ssion of Gen
nique, 400 E
ern blot an
the cDNA
ch library) a
8 and 72 clo
xpression in
 of 47 clone
l hybridizat
from diabet
ce Homolog
eir different
ompared to t
he found ge
howed norm
group show
lar to those 
e similar in
renal vascu
ion profilin
as STZ-ind
e studies h
eir precise m
onsidered b
t can serve a
nes 
EST’s were 
nalysis was 
A libraries; 
and hybridiz
ones from th
n the presen
es from the 
tion pattern 
tic kidney ra
gy of EST’s
tial expressi
those of the
nes are sho
mal morpho
wed glomeru
reported by
n type 1 and
ulature) can 
ng related 
duced diabe
have identif
molecular m
iomarkers [
as molecula
obtained (2
performed 
however, 
zed with RN
he up- and d
nce of DN in
subtractive
of cDNA a
at. Panel rig
 
ion pattern,
e database fr
own in Tabl
ologies of g
ular damag
y Omotayo e
d type 2 di
be affected
with diabet
etes in mice
fied genes 
mechanisms
[3]. Therefo
ar targets to
200 down- a
to confirm
only 200 
NA probes f
down-regula
n STZ-induc
e library obt
arrays from
ght: probe fr
 were selec
rom NCBI b
les 2 and 3
glomeruli a
e and sever
et al. [19]. I
iabetes and 
d [20]. 
tic nephrop
e and rats, 
involved in
s have rema
ore, it is im
o broaden th
and 200 up-
m the differe
EST’s wer
from either 
ated librarie
ced rats. Ty
ained is sho
the library 
rom healthy
cted and seq
by means o
. Based on 
and tubules 
re destructio
It has been o
all renal c
pathy has b
as well as 
n the devel
ained unclea
mportant to 
he developm
regulated) f
ential expre
re transferr
diabetic or 
es, respectiv
ypical expre
own in Figu
obtained by
y rat kidney
quenced. Th
f the BLAS
this, possib
843
(Figure 1a
on of tubule
observed tha
ompartmen
been studie
spontaneou
lopment an
ar and only 
identify new
ment of nove
from kidney
ession of th
red to nylo
healthy rat
vely, showe
ession patter
ure 2. 
y SSH. 
. 
 
he sequence
ST algorithm
ble function
35 
 
a). 
es 
at 
nts 
ed  
us 
nd 
a 
w 
el 
ys 
he 
on 
ts. 
ed 
rn 
es 
m, 
ns  Int. J. Mol. Sci. 2011, 12 8436 
 
for the sequenced EST’s were grouped in: (1) Metabolism protein; (2) transporters and channels;   
(3) hypothetical proteins; (4) transcription factors; and (5) unknown function.  
Table 2. Down-regulated genes isolated by subtractive suppressive hybridization from the 
kidneys of STZ-induced rats after four weeks.  
Function Accession  No.  Blast  result  pb 
Fold 
change 
(a) Metabolism 
proteins 
NM_172034 
Farnesyltransferase beta subunit 
(Fntb)  
281 0.742 
 AA874879.1  NADH  dehydrogenase    388  0.623 
 
NM_017034 
Threonine-protein kinase  
(PIM-1) 
675 0.502 
 NM_021577  Argininosuccinate  lyase  (ASL)  626  0.517 
 
NM_053774.2 
Ubiquitin-specific peptidase 2 
(USP2) 
251 0.676 
 
NM_022243.1 
Hydroxyisobutyrate 
dehydrogenase (Hibadh)  
368 0.954 
 
NM_022933.2 
Helicase DNA binding protein 8 
(Chd8) 
202 0.922 
 
NM_031795.2 
UDP glucose ceramide 
glycosyltransferase (Ugcg)  
346 0.564 
 AF227741.1 
Serine/threonine-protein kinase 
(WNK1)  
423 0.870 
 
NM_024160.1 
Cytochrome b-245, alpha 
polypeptide (Cyba) 
663 0.792 
 NM_001009668.1
Electron-transfer-flavoprotein, 
alpha polypeptide (Etfa) 
373 0.506 
 M29579.1  Glutamine-synthetase  (GS)  372  0.640 
 
XM_221132.5 
Ubiquitin-conjugating enzyme 
E2O (Ube2o) 
226 0.858 
(b) Transporters 
and channels  NM_052983.2 
Solute carrier family 5  
(sodium iodide symporter), 
member 5 (Slc5a5) 
280 0.906 
  NM_016996.1  Calcium-sensing receptor (Casr)  417  0.413 
 
D50497.1 
CIC-type chloride channel  
(ClC-5) 
242 0.786 
(c) 
Transcription 
factors 
NM_001191711 
DEAD box polypeptide 20 
(Ddx20) 
519 0.793 
 
NM_013141.2 
Peroxisome proliferator-activated 
receptor delta (Ppard) 
580 0.631 
2.5. Differential Expression of Selected Transcripts from the Subtractive Library 
In the present study, the main objective was to identify some differentially expressed genes involved 
in DN. As aforementioned, based on hybridization signals, 160 EST’s were selected for sequencing, Int. J. Mol. Sci. 2011, 12 8437 
 
from which 72 were down- and 88 over-expressed genes (Tables 2 and 3, respectively). BLAST 
analysis revealed that at least 80% of the genes had been previously reported in the GeneLibrary 
database. However, 20% of these fragments did not match any gene published in the gen bank, thus 
raising the possibility of newly identified genes. 
Table 3. Up-regulated genes isolated by subtractive suppressive hybridization from the 
kidneys of STZ-induced rats after four weeks. 
Function  Accession No.  Blast result  pb  Fold change
(a) Metabolism 
proteins  NM_001009637.1  Leucyl-tRNA synthetase (Lars)  511  1.011 
  NM_001039346.1  Zinc finger, DHHC-type 
containing 16 (Zdhhc16)  250 1.360 
  NM_001159739.1  Glutathione-S-transferase 
(Gsta5)   237 1.133 
  NM_032080.1  Glycogen synthase kinase 3 beta 
(Gsk3b)   302 1.143 
  NM_001007620.1  Pyruvate dehydrogenase beta 
(Pdhb)  200 1.697 
  NM_134417.1  Inositol polyphosphate 
multikinase (Ipmk)  295 1.473 
  NM_001004214.1  NAD(P)H dehydrogenase, 
quinone 2 (Nqo2)  596 1.010 
  NM_ NP_446292.2 Gamma-glutamyltranspeptidase 1 
(Ggtp1)  636 1.755 
  NM_001007235.1  Inositol 1,4,5-triphosphate 
receptor, type 1 (Itpr1)  504 1.093 
  NM_012570.1  Glutamate dehydrogenase 1 
(Glud1)  327 1.103 
  NM_001004252.1 
NM_017072.1 
Phenylalanyl-tRNA synthetase,  
beta subunit (Farsb)  
Carbamoyl-phosphate synthase 
subunit 1 (Cps1) 
301 
591 
1.012 
1.383 
(b) Transporters 
and channels  NM_173338.1  Solute carrier organic anion 
transporter family (SIco6c1)  414 1.777 
 
NM_134468.1 
Calcium- and calmodulin- 
dependent protein kinase type 1 
(Camk1) 
256 1.226 
 
NM_012517.2 
Calcium channel,  
voltage-dependent, L type, alpha 
1C subunit (Cacna1c) 
200 1.379 
(c) Transcription 
factors  NM_001127373.1  ADNP homeobox 2 (Adnp2)   380  1.967 
  NM_031346.1  ROD1 regulator of differentiation 
1 (S. pombe)(Rod1)  204 1.963 
  NM_001033694.1  Sterol regulatory element binding 
transcription factor 2 (Srebf2)  766 1.331 
   Int. J. Mol. Sci. 2011, 12 8438 
 
2.6. Related Function of Transcript Selected from the Subtractive Library  
2.6.1. Metabolism Protein  
Table 2 (Section a) and Figure 3a show the down-regulated genes related to several enzymes that 
participate in cellular metabolism, e.g., NADH dehydrogenase. This enzyme plays a fundamental role 
in cellular respiration. This protein is located in the inner mitochondrial membrane and catalyzes the 
transfer of electrons from NADH to coenzyme Q (CoQ) in the electron transport chain and this activity 
is related to maintenance of a transmembrane proton gradient used to produce ATP, since 
mitochondrial energy production is essential for all cellular processes and organ functions. In acute 
kidney injury (AKI), de-energization of the mitochondria and loss of mitochondrial proteins may lead 
to irreversible cell injury, limiting restoration of organ function. In primary cultures of renal proximal 
tubule cells (RPTCs), recovery from oxidant-induced mitochondrial dysfunction was related to an 
increased expression of the mitochondrial proteins NADH dehydrogenase and ATP synthase β, and 
elevated mitochondrial respiration rates and ATP levels [21]. In the present study, we found that 
NADH dehydrogenase was down-regulated in diabetic animals, suggesting that the electron transport 
chain could be decreased in this condition, thus altering energy production (ATP). Argininosuccinate 
lyase (ASL) enzyme was also down-regulated. The kidney plays a key role in arginine metabolism. 
Renal L-arginine (L-Arg) synthesis requires citrulline, made primarily in the small intestine, which is 
then taken up into the kidney and converted by argininosuccinate synthase (ASS) and 
argininosuccinate lyase (ASL) into L-Arg. The L-Arg is then released into the circulation via the renal 
vein, taken up into cells, and utilized in several pathways including nitric oxide (NO) synthesis. 
Humans and animals with renal disease, show increases in plasma citrulline correlating with   
decreased renal function [22]. In fact, renal L-Arg production is impaired quite early before any 
significant structural damage is evident. The fall in arginine production is due to an early loss of ASS 
and ASL for conversion of citrulline, along with a later reduction in citrulline uptake. In chronic 
kidney disease (CKD), ASL density was unchanged at 1–2 weeks after injury; however, when adjusted 
for viable renal mass, there was a 60% reduction in total renal ASL abundance at 1–2 weeks after 
injury, and no change was observed in more severe CKD [23]. In our experiment, EST’s of ASL were 
repressed (Table 2, Section a, and Figure 3a) in diabetic kidney compared to healthy rat kidney, 
suggesting a probable reduction in L-Arg concentration and, therefore, contributing to the resulting  
NO deficiency. 
Also, WNK1 was found to be down-regulated in diabetic conditions (Table 2, Section a and   
Figure 3a). WNK are protein kinase and WNK1 has multiple alternatively spliced isoforms including 
long forms expressed in the whole nephron at a low level (L-WNK1) and a kidney specific form  
(KS-WNK1) distributed in the distal convoluted tubule, the connecting tubule and the cortical 
collecting duct. KS-WNK1 is 1700 aminoacids in length and lacks aminoacids 1-437 of the long  
L-WNK1 isoform that are encoded by exon 1–4. L-WNK1 decreases cell surface abundance of renal 
K
+ channel ROMK1 (renal outer medullary potassium (K) channel 1) and induces a decrease in   
K
+ secretion by the kidney contributing to hyperkalemia. K
+ secretion by kidney is critical for 
controlling serum K
+ levels and overall K
+ homeostasis. KS-WNK1 is an important physiological 
antagonist of L-WNK1, and the ratio of L-WNK1 to KS-WNK1 regulates surface abundance of Int. J. Mol. Sci. 2011, 12 8439 
 
ROMK1 and renal K
+ excretion [24,25]. Unexpectedly, diabetic kidney showed a down-regulation of 
WNK1 compared to healthy kidney, thus allowing potassium to exit through transporter protein 
ROMK, which is usually negatively modulated by WNK1. 
Figure 3. Northern-blot analysis performed in selected genes of the down-regulated library. 
 
Likewise, inositol polyphosphate multikinase (IPMK) is a member of the IP6 kinase family of 
enzymes that generates several inositol phosphates. IPMK also possesses phosphatidylinositol 3-kinase 
(PI3K) activity, specifically phosphorylating the phosphatidylinositol (4,5)-bisphosphate (PIP2) to 
generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a second messenger known to promote 
cellular growth, proliferation, survival, and migration. Genetic deletion of IPMK impairs Akt signaling 
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experiment, over-expression of IPMK (1.4 fold change, Table 3 Section a, and Figure 4a) was found in 
diabetes condition, and this effect could be related to an increase of cell proliferation of both 
macrophages and myofibroblasts, likely contributing to the tubulointerstitial infiltration observed in DN. 
In addition, gammaglutamyl transpeptidase (GGTP1) was found to be over-expressed in kidney of 
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membrane lipid peroxidation that could contribute to a certain degree to morphological changes of 
tubular cells [27]. In our study, we evaluated the levels of TBARS in kidney of diabetic animals and their 
content was higher (638 nmol/mg tissue) compared to that of healthy animals (211 nmol/mg tissue); 
therefore, the results demonstrated the presence of lipid peroxidation in diabetic kidney. 
Figure 4. Northern-blot analysis performed in selected genes of the up-regulated library. 
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by reducing the urinary excretion of ammonia in the form of ammonium ions [28]. A study 
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acidosis [29]. In our results, the expression of GS in kidney of diabetic rats was repressed by 40% 
(Table 2 Section a, and Figure 3a).  
2.6.2. Transporter and Channels  
Table 2, Section b, is a summary of down-regulated genes encoding transporters and channels in 
kidney under diabetic conditions. In this regard, the extracellular calcium-sensing receptor (CaSR) 
gene is shown in Table 2, Section b, and Figure 3b. In the kidney, the CaSR has several different 
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actions, leading to enhanced reabsorption of sodium chloride and increased calcium excretion in the 
renal tubules [30]. In the nephrectomy rat model, CaSR mRNA expression and CaSR protein levels 
were reduced by 35 and 38%, respectively, compared to those observed in control animals. The results 
suggest that renal CaSR expression is reduced in chronic renal insufficiency and this may play a role in 
disordered mineral ion including hypocalciuria [31]. These results are in accordance with those found 
in our study. 
Regarding the up-regulated genes, the calcium- and calmodulin- dependent protein kinase (CamK) 
gen was over-expressed (1.2 fold change) in kidneys of STZ-induced diabetic rats (Table 3, Section b, 
and Figure 4b).  
Free cytosolic calcium level plays a crucial role in many important cellular processes, such as gene 
transcription, cell proliferation and differentiation, and apoptosis. Calcium ions are also known to 
regulate several enzymes and to interact with a large number of other calcium-binding proteins that 
participate in several cellular signaling pathways [32]. 
The Multifunctional CamK is a ubiquitous enzyme that is present in all cell types thus far examined. 
This enzyme is so named because of its requirement for calcium-bound calmodulin for activation and 
its ability to phosphorylate and alter the function of a variety of substrates. In mesangial cells, Src 
protein tyrosine kinases act downstream of CamK in a signaling pathway in which Ca
2+
i induces the c-
fos promoter and increases DNA synthesis, resulting in hypertrophy, hyperplasia, and/or expansion of 
the mesangial matrix [33]. 
2.6.3. Transcription Factors 
In the down-regulated library, the transcription factor peroxisome proliferator-activated receptor 
delta (PPARδ or PPARD) was also identified (Table 2, Section c, and Figure 3c). PPARδ is a   
ligand-activated transcription factor that belongs to the nuclear hormone receptor family and plays a 
key role in cell survival [34,35]. In comparison with PPARα and PPARγ, PPARδ is ubiquitously 
expressed in all nephron segments within the kidney; in addition, this is the predominant isotype in the 
proximal straight tubule [36]. Because of this high expression, PPARδ would contribute to survival of 
proximal tubular cells in ischemic acute renal failure [37]. However, with more sustained 
ischemia/reperfusion, epithelial cells of the proximal tubule undergo necrotic or apoptotic cell   
death, thus contributing in part to the inflammatory response after renal ischemia/reperfusion. 
Letavernier et al. [37] found that the PPARδ ligands could directly trigger inflammation in endothelial 
cells. Also, PPARδ ligands have shown to inhibit the expression of proinflammatory cytokines. 
Therefore, the repressed expression (0.6 fold change) of PPARδ found in our experiment (Figure 3c) 
could be related with renal dysfunction, since PPARδ exerts a strong protection against renal failure. 
On the other hand, several up-regulated transcription factors were identified (Table 3, Section c, and 
Figure 4c), such as the sterol regulatory element-binding protein-2 (SREBP2). SREBP2 is a member of 
the sterol regulatory element binding proteins (SREBPs) involved in the regulation of lipid homeostasis. 
SREBP2 is a transcription factor regarded as the main regulator of cholesterol homeostasis and an 
increased level of SREBP-2 could be responsible for hypercholesterolemia generally observed in 
experimental chronic renal failure [38]. Int. J. Mol. Sci. 2011, 12 8442 
 
It has been shown that an increased renal expression of SREBP1 and SREBP2 results in an excessive 
accumulation of triglycerides and cholesterol in renal structures, and this lipid accumulation is 
associated with glomerulosclerosis and proteinuria [39]. In this study, SREPB2 was over-expressed  
(1.3 fold change) in the kidney of diabetic rats compared to healthy rats (Figure 4c) [40]. 
2.6.4. Unknown Genes 
From the library of down-regulated genes, 25 EST’s with unknown functions were found with a 
repression ratio of between 0.413 and 0.921 times, compared to those of healthy rats. On the other hand, 
19 EST’s with unknown functions were obtained in the library of up-regulated genes, with an   
over-expression ratio of between 1.3 and 2.5 times, compared to those of the healthy group.   
These represent 24.1 and 17.2% of the total EST’s from down- and up-regulated libraries   
(Figure 5a,b, respectively). 
Figure 5. Renal genes isolated by subtractive suppressive hybridization from (a) down- 
and (b) up-regulated libraries of STZ-induced rats. 
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The overall results are summarized in Figure 5, where it shows the percentage of EST’s found in 
the down- and up-regulated libraries, based on their possible gene functions. For down-regulated genes: 
(1) Metabolizing enzymes 20.2%; (2) transports and channels 9.1%; (3) hypothetical proteins 19.3%; 
(4) transcription factors 10.2%; and (5) unknown function 24.1%. Likewise, for up-regulated genes: (1) 
Metabolizing enzymes 20.9%; (2) transports and channels 3.6%; (3) hypothetical proteins 17.2%; (4) 
transcription factors 6.3%; and (5) unknown function 17.2%. 
In this study, it was possible to identify genes during the early phases of diabetic nephropathy, such 
as IPMK and WNK1, which have been previously reported in kidney but had not been associated with 
the development of this disease. 
3. Experimental Section  
3.1. Induction of Diabetes and Experimental Protocol 
Animal experiments were conducted in accordance with ethical guidelines of the University of 
Queretaro. Male Wistar rats (weighing 250–300 g) were obtained from Rismart S.A., Mexico. The 
animals were housed at 20–25 °C with a 12-h light-dark cycle, through the experimental period. 
Animals were allowed free access to water and a base diet (Zeigler rat chow) containing: protein, 18%; 
fat, 4%; carbohydrates, 54%; fiber, 5%; and sufficient minerals and vitamins to maintain the health of 
the rats. Diabetes was induced by a single intraperitoneal injection of freshly prepared STZ (Sigma 
Chemical Company, USA, 50 mg/kg body weight; dissolved in a citrate buffer, 0.01 M, pH 4.5) after 
overnight food deprivation. Nondiabetic rats received the same volume of vehicle (citrate buffer). 
After 1 week, rats with blood glucose ≥250 mg/dL were considered diabetic for this experiment. Both 
nondiabetic (group 1) and diabetic (group 2) groups included eight rats each one and were fed with 
base diet. Blood samples were taken from tail vein and the glucose concentration was measured by a 
glucose oxidase assay (Glucose Accutrend, Roche, Germany) and measured by a reflective glucometer 
(Accutrend, GC). One day before sacrifice, animals were housed in metabolic cages to obtain urine for 
determination of biochemical parameters related to DN. At week four, animals were anaesthetized and 
blood samples were withdrawn by cardiac puncture and the serum was immediately separated from the 
blood samples by centrifugation and stored at −80 °C until analysis. Kidneys were immediately 
removed, thoroughly washed with cold-ice saline phosphate buffer, and weighed. A piece of kidney 
was stored in formaldehyde solution and another part was frozen in liquid nitrogen and stored at  
−80 °C until analysis.  
3.2. Assays of Serum, Urine and Kidney Tissue Samples 
DN was assessed biochemically by determining urine volume, urinary urea, albumin, protein and 
also blood urea. Likewise, blood and urine creatinine levels were used for quantification of creatinine 
clearance (Ccr). All these parameters were measured using commercial kits (Randox Laboratories Ltd., 
UK). Creatinine clearance (CCr) was calculated on the basis of urinary Cr, serum Cr, urine volume, and 
body weight using the following equation: CCr (mL/min) = [urinary Cr (mg/dL) × urine volume 
(mL)/serum Cr (mg/dL) × 1440 (min)]. Also, kidney/body weight ratio was calculated. Data were 
expressed as relative kidney weight (percentage of body weight). Serum insulin levels were determined Int. J. Mol. Sci. 2011, 12 8444 
 
under fasting conditions using a commercial kit (Millipore, USA) according to the   
manufacturer’s instructions. 
3.3. Kidney Histopathology  
Renal tissues were fixed in 4% paraformaldehyde solution and embedded in paraffin. Sections   
were cut at 7 µm with a microtome and deparaffined with xylene. The sections were stained with 
Hematoxylin-Eosin (H-E) and observed under a light microscope at magnifications of 200×. 
3.4. RNA Isolation  
Total RNA of diabetic and normal rats was obtained by RNEASY protocol (QIAGEN, Hilden, 
Germany). Integrity and size of RNA was analyzed by means of electrophoresis in agarose gel with 
formaldehyde. RNA quantification and assessment of purity were measured spectrophotometrically by 
the absorbance ratio (260/280 nm). 
3.5. PCR-Selected cDNA Subtraction 
1 µg of total RNA of each condition (healthy and diabetic) was used as template for synthesizing 
the first cDNA chain with Superscript II reverse transcriptase (Life Technologies, Rockville, MD, 
USA) and the protocol of SMART™ cDNA Synthesis, following the instructions of the supplier 
(Clontech, Palo Alto, CA, USA). The cDNA was amplified by long distance PCR (LD-PCR) with 15, 
18, 21, 24, and 27 parallel cycles to compare and guarantee an optimal and suitable amount of PCR 
products for the construction of the cDNA subtractive library [12]. CROMA-SPIN
TM columns 
(Clontech, Palo Alto, CA, USA) were used to guarantee highly pure cDNA.  
Subtractive hybridization by suppression (SSH) was carried out using the PCR-Select™ cDNA 
subtraction kit (Clontech, Palo Alto, CA, USA). Tester and driver cDNAs were digested using RsaI to 
yield blunt ends. In order to obtain up-regulated genes in kidney of diabetic rats, the mRNA of these 
rats was employed as the “tester” and kidney mRNA of healthy rats as the “driver”. On the other hand, 
to obtain down-regulated genes from kidney of diabetic rats, kidney mRNA of diabetic rats was 
employed as the “driver” and kidney mRNA of healthy rats as the “tester”. The tester cDNA fragments 
were proportionally divided into two aliquots and each one ligated in separated reactions with adapter 
1 and adapter 2, resulting in two tester cDNA populations. A small amount of each tester population 
was mixed with an excess of driver population (5 µg), subsequently heat-denatured, and allowed to 
anneal for 8 h at 68 °C. The two samples from the first hybridization were combined and annealed 
overnight at 68 °C with additional fresh-denatured driver cDNA. A primary PCR was conducted to 
amplify those cDNAs that represented differentially expressed genes. A second PCR was carried out 
using nested primers 1 and 2 R (Clontech, Palo Alto, CA, USA) to reduce the level of unspecific 
amplification and for the preparation of Northern blot probes. The products of the secondary PCR 
amplification were monitored by agarose gel electrophoresis, and the fragments larger than 250 bp 
were cut out of the agarose gel using a sterile scalpel and purified by using a QIAEXII protocol 
(QIAGEN, Hilden, Germany). 
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3.6. Cloning, Screening, and cDNA Sequencing Subtracted  
The differential PCR fragments were ligated into the PCR 4-TOPO cloning vector, according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). 2 µL of these ligation reactions was 
used to transform chemically competent Escherichia coli TOP 10 cells (Invitrogen, Carlsbad, CA, 
USA). The transformed cells were planted on Luria-Bertani (LB) agar containing kanamycin, and the 
white colonies were selected. Individual E. coli colonies were inoculated into LB media containing 
kanamycin/ampicillin and shaken overnight at 37 °C. Inserts were screened by restriction analysis 
using EcoRI (Invitrogen, Carlsbad, CA, USA) and agarose gel electrophoresis. Each selected colony of 
the library was kept in cryogenic vials with 500 µL of each culture and 500 µL of 100% sterilized 
glycerol. The collection of colonies (library of differentially expressed genes) was kept at −80 °C. The 
products were sequenced and subject to homology search by using BLAST program at the web site of 
National Center of Biotechnology Information [41]. 
3.7. Northern Blot Analysis 
To confirm the expression status of the genes isolated by SSH, Northern blot analysis was performed 
as previously described [42]. Briefly, the mRNA was isolated from kidneys of diabetic and healthy rats 
as described above. Of the isolated mRNA, 2 μg were spotted into positive-charged nylon membranes 
(Hybond
TM-N
+ Amersham Bioscience, UK Limited) using the slot manifold (Amersham Bioscience). 
Probes were created from the previously isolated SSH fragments by incorporating fluorescein-11-dUTP 
(Gene Images CDP-star random prime labeling module) according to the manufacturer’s instructions 
(Amersham Pharmacia Biotech Inc. Piscataway, NJ, USA). After ultraviolet (UV) cross-linking the 
RNA to the membranes (UV stratalinker 2400, stratagem Co., La Jolla, CA, USA), the blots were 
hybridized, washed, and detected whit the Gene Images CDP-star detection module (Amersham 
Pharmacia Biotech Inc. Piscataway, NJ, USA) using anti-fluorescein alkaline phosphatase conjugated 
and CDP-star detection reagent (Amersham Pharmacia Biotech Inc. Piscataway, NJ, USA) and 
followed by 3 h of exposure.  
3.8. Statistical Analysis of Expression Data 
The  T-student analysis was performed to evaluate the significant differences (P  ≤ 0.05) in the 
expression levels of the diabetic kidney against the healthy kidney (JMP 5.0.1., software).  The 
differential expression analysis consisted of the comparison of band intensity for each gene. The 
confirmation of the results was validated by Northern blot analysis. The normalization was based on the 
ratio between the gene of each diabetic control absolute values followed by the ratio of healthy control 
relative value expressed as fold of change in Tables 2 and 3. The cut off value to assign genes that 
increase/decrease expression was based on the relative value 1.0 produced by the normalization ratios. 
4. Conclusions  
400 clones were obtained to constitute the up- and down-regulated differentially expressed cDNA 
libraries from rat kidneys and 200 EST’s were randomly selected and sequenced in order to create a 
transcriptomic profile. Although several EST’s showed homology with genes whose function could Int. J. Mol. Sci. 2011, 12 8446 
 
suggest a possible role in the pathogenesis of DN, functional genomics studies need to be performed in 
order to prove their particular roles in DN. 
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